Morphological and Prognostic Characteristics of Breast Cancer in Women Living in the Sakha Republic (Yakutia)

ORIGINAL ARTICLE
Maria P. Kirillina, Irina V. Kononova, Sargylana I. Sofronova, Petr M. Ivanov, Aytalina S. Golderova

 
International Journal of Biomedicine. 2021;11(2):201-205.
DOI: 10.21103/Article11(2)_OA13
Originally published June 5, 2021

Abstract: 

Background: This article presents the results of the analysis of the clinical and morphological examination of breast cancer (BC) in women of the Republic of Sakha (Yakutia) (RS(Y)).
Methods and Results: The object of the study was fragments of breast tissue from 294 women who underwent surgical treatment and/or needle biopsy. By ethnicity, there were 118(40.1%) women of indigenous nationalities and 176(59.9%) women of non–indigenous nationalities. The greatest number of cases of BC was registered in the age group of 50-59 (32.6%). The age group of 40-49 was in second place (20.4%). Among the indigenous population, women in the age groups of 40-49 years (23.7%) and 50-59 years (26.3%) predominated.  The age groups of 50-59 years (36.9%) and 60-69 years (22.2%) predominated among the non-indigenous women.
Tumors with a size of 2 cm to 5 cm prevailed; they were detected in 185(62.9%) women. Tumors with a spread to the chest wall and skin develop more often in women of non-indigenous nationalities (15.9% of cases), than in women of indigenous nationality (6.8% of cases). Regardless of ethnicity, the most common histological form of BC in women of the RS(Y) was infiltrative ductal cancer (65.3%). Cancer staging according to the TNM staging system showed that n the age group of women under 39 years, Stage IIIB+IIIC  (43.2%) was most often registered (p=0.01), while in other age groups, Stage IIA (32.4%) was more often noted.
Conclusion: Our findings suggest that further investigation of the peculiarities of the course of BC in the female population of Yakutia would lead to much improved methods of diagnosis and treatment.

Keywords: 
breast cancer • diagnosis
References: 
  1. Pisareva LF, Boyarkina AP, Panferova EV et al. The incidence of breast cancer in the female population of the Irkutsk region. Risk factors. Siberian Journal of Oncology. 2012:5(53):12 - 17.
  2. Pisareva LF, Odintsova IN, Boyarkina AP. Features of the incidence of breast cancer in the population of the region of Siberia and the Far East, taking into account the factor of migration. Russian Journal of Oncology.  2006; (2):48-50.
  3. Kulakov VI, Tokhiyan AA. Problems of malignant neoplasms of the reproductive system in the practice of a gynecologist. Journal of Obstetrics and Women's Diseases.  2001; 30(1):9–12.
  4. DePinho RA. The age of cancer. Nature. 2000 Nov 9;408(6809):248-54. doi: 10.1038/35041694.
  5. Dulganov KP, Dulganov PK, Dulganov VK. Epidemiology of malignant tumors in the Republic of Buryatia.  Ulan-Ude: Buryat Publishing House. State University;, 2001. [In Russiuan].
  6. Bozhok AA, Semiglazov VF, Semiglazov VV, et al. Prognostic and predictive factors in breast cancer Problems of Oncology. 2005;51(4):434-443.
  7. Pisareva LF, Odintsova IN, Ananina OA, Muranova OYu, Guruina LI.. Epidemiology of breast cancer in the Primorsky Krai. Siberian Journal of Oncology. 2010;1:50-55.
  8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Histopathology. 2002 Sep;41(3A):151-2, discussion 152-3. PMID: 12405945.
  9. Loskutova KS, Argunov VA, Innokentieva AS, Sivtseva TP, Kirillina MP. Immunomorphological characteristics of the hormonal status of primary breast cancer in the Republic of Sakha (Yakutia). Yakut Medical Journal. 2009;(1):46-49.
  10. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002 Nov;76(1):27-36. doi: 10.1023/a:1020299707510.

Download Article
©2021 International Medical Research and Development Corporation.